Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Original

Efficacy of drug regimen with and without oseltamivir in hospitalized patients with COVID-19: A retrospective study

Fazlollah Shokraia, Saeed Rezepoorb, Masoud Najafic,d, Mohsen Asadie, Mohammad Karimi alavijef, Moussa Abolhassani,g, Mohammad Hossein Moieneddin,h, Amir Muhammad Ashrafi,l, Narges Gholipourj, Parisa Nadereb, Jamshid Yazdani Charatil, Reza Alizadeh-Navaeim, Majid Saeedi,n, Mohsen Heidaryo,⁎, Mostafa Rostamnezhadp,*

a Department of Medical Genetics, Faculty of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
b Department of Radiology, Imam Khomeini Hospital, Amol, Iran
c Medical Technology Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran
d Radiology and Nuclear Medicine Department, Kermanshah University of Medical Sciences, Kermanshah, Iran
e Department of Hematology and Blood Banking, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
f Department of Infectious Disease, Imam Reza Hospital, Amol, Iran
g Inv. Member, International Federation of Inventors’ Associations-IFIA, Geneva, Switzerland
h Student Research Committee, Amol Faculty of Nursing, Mazandaran University of Medical Sciences, Sari, Iran
i Student Research Committee, Amol Faculty of Nursing, Mazandaran University of Medical Sciences, Sari, Iran
j Department of Critical Care Nursing, School of Nursing and Midwifery (Nasibeh), Mazandaran University of Medical Sciences, Sari, Iran
k Department of Biology, Faculty of Cellular and Molecular Sciences, Central Tehran Branch, Islamic Azad University, Tehran, Iran
l Department of Biostatistics, Faculty of Health, Mazandaran University of Medical Sciences, Sari, Iran
m Gastrointestinal Cancer Research Center, Non-communicable Diseases Institute, Mazandaran University of Medical Sciences, Sari, Iran
n Department of Pharmaceutics, Faculty of Pharmacy, Mazandaran University of Medical Science, Sari, Iran
o Cellular and Molecular Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran
p Department of Medical Physics, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran

ABSTRACT

Introduction: Coronavirus disease 2019 (COVID-19) is the most critical issue in nowadays medicine. We aimed to evaluate the use and therapeutic outcomes of oseltamivir, an antiviral drug for patients with COVID-19.

Materials and method: In an observational study conducted at Imam Khomeini Hospital in Amol, Iran, data for 544 patients with laboratory and CT scan result confirmed COVID-19 were retrospectively collected between February 24th and April 13th 2020. To compare the characteristics of patients based on gender, the chi-square test was used. Logistic regression was used to evaluate the effect of oseltamivir on the outcome of treatment. Logrank test were used to compare the length of hospital stay in people treated with oseltamivir and drugs other than oseltamivir.
Results: Kaplan–Meier and logrank test showed no significant reduction in hospitalization time and survival rate following treatment with oseltamivir. However, a significant increase in lymphocytes count and reduction of C-reactive protein (CRP) level detected.

Conclusion: Administration of oseltamivir for patients with COVID-19 didn’t show any improvement in hospitalization duration and survival rate.

© 2022 Elsevier España, S.L.U. All rights reserved.

Introduction
Corona virus disease 2019 (COVID -19) is the most challenging pandemic diseases in the century 21. COVID-19 was diagnosed in Wuhan, China in December 2019, and then spread out in all world during some months. To date, several millions people have been confirmed with positive COVID-19 in worldwide. Furthermore, a large numbers of people have been died because of severe side effects associated with COVID-19. Epidemiological studies suggest that most people with COVID-19 may show mild or moderate symptoms. However, side effects with this disease can be killer in some patients, especially aged patients and patients with underlying medical conditions like patients with kidney diseases and hypertension, diabetes, and also patients that suffer from cardiac and lung diseases. Mortality rate for patients with COVID-19 is very different dependent on sex, age, and underlying diseases. It has been reported that COVID-19 may cause death in 0.03 patients without underlying health conditions and 0.12 patients with underlying health conditions. Furthermore, mortality rate has a direct relation with age.

Iran was one of the first countries that confirmed outbreak of COVID-19. The numbers of infected people with COVID-19 are growing and now approved vaccine are available for control of this pandemic. Furthermore, there is no certain cure for COVID-19. Scientists in worldwide trying to reduce mortality of this disease via alleviation of its side effects and also recommending some antiviral drugs. Oseltamivir (phosphate) is one of common antiviral drugs that is prescribed for patients with flu. Oseltamivir is able to attack the flu virus directly. It inactivates neuraminidase enzyme, a critical enzyme which is expressed virus and facilitate its migration. By inhibition of this pathway, oseltamivir can prevent infection of new cells by flu virus and also alleviate symptoms associated with type A and B flu viruses.

According to the Iranian national guidelines, oseltamivir was part of the treatment protocol for patients with COVID-19, which was subsequently removed from the national protocol. In the current retrospective cohort study, we assessed the possible effect of oseltamivir for patients with positive COVID-19. This is one of the few studies that investigated the effect of oseltamivir for COVID-19 patients. For detection of lung pneumonitis, we used computed tomography (CT) scan. As reported by previous study, CT scan has a high sensitivity for detection of lung changes and its sensitivity may be higher than real-time polymerase chain reaction (RT-PCR) method. CT scan has a higher sensitivity for the detection of COVID-19, however, some clinical evaluations suggest that it has a lower specificity compared to RT-PCR. Recently, some studies have shown that CT scan can be used to detect infection and also severity of
pneumonia in patients with COVID-19.\textsuperscript{27-30} A high resolution of CT scan can help to find and evaluate the condition of patients with COVID-19.\textsuperscript{31-33}

**Methods**

**Ethics approval**

The study was reviewed by the ethics committee of Mazandaran University of Medical Sciences and was approved with the code of IR.MAZUMS.REC.1399.074.

**Study setting**

This retrospective cohort study was performed at Imam Khomeini Hospital in Amol, Iran. This hospital is one of the few centers for the treatment of COVID-19 in northern Iran (Mazandaran province). The medical records of patients were retrospectively collected between February 24th and April 13th 2020.

**Participants**

The main criterion for entering the study for all people of different ages was referring to Imam Khomeini Hospital in Amol city and proving their COVID-19 with CT scan or Reverse Transcription Polymerase Chain Reaction (RT-PCR) assay of nasopharyngeal swab specimens. The participants had not received the COVID-19 vaccines. Completing the course of treatment and determining the individual’s disease status were other criteria for entering the study. Personal satisfaction and discharge from the hospital and the incompleteness of the patient’s file and not knowing the individual’s disease status were also exclusion criteria. Sampling was done by non-probability method and Convenience. Data were collected for 544 patients during the study period (Fig. 1). No patient received vaccination before infection with COVID-19.

**Data collection**

Demographic, epidemiological, laboratory, pharmacological information, vital and clinical signs, length of hospital stay, and outcome of treatment (in the form of recovery, partial recovery, and death) were obtained using a standardized checklist from patients’ files. Complete relief of symptoms including cough, fever and chills, shortness of breath, etc. was considered as recovery and partial improvement of these symptoms was considered as partial recovery. Data obtained were reviewed by statisticians, pharmacists, hematologists, radiologists and nurses, and then the discrepancies in the files were resolved in consultation with infectious disease specialists. Underlying health conditions, common medications, smoking history, patient addiction, and hospitalization history for any reason were also obtained using self-reporting.

**Statistical analysis**

To describe the data, Mean ± SD was used for quantitative variables and frequency tables were used for qualitative variables. To compare the characteristics of patients based on gender, the chi-square test was used. Logistic regression with controlling the intervening variables was used to evaluate the effect of oseltamivir on the outcome of treatment. Kaplan-Meier and logrank test were used to compare the length of hospital stay in people treated with oseltamivir and drugs other than oseltamivir. SPSS software version 25 was used for analysis and the significance level was considered 0.05.

**Results**

The Chi-square test was used to compare the patient’s characteristics (risk factors, symptoms, and demographic characteristics) by gender. As we showed in the Table 1, approximately 30% of patients were diabetic, which was higher in women (P value = 0.02). In the case of blood pressure, 33.5% of patients had hypertension, which was 42% in women (P value = 0.01). In other chronic diseases, it was more common in women (P value = 0.001). Smoking in men was more than women (P value = 0.02). In other cases, as shown in the Table 1 no significant difference was observed between men and women. The medication regimen of most patients contained hydroxychloroquine, azithromycin, and lopinavir/ ritonavir. The Chi-square test was used to compare the group receiving oseltamivir or not receive oseltamivir. No significant difference was observed between the two groups in terms of treatment (recovery, partial recovery, and death) and CT scan results. Also, no significant difference was observed in laboratory data except for lymphocytes and CRP level, which a significant increase in lymphocytes count and reduction of C-reactive protein (CRP) level detected (Table 2).

Finally, to show the effects of risk factors and demographic characteristics on the outcome (survival or death) of
| Characteristics                                      | Female   | Male    | All      | Sig  |
|------------------------------------------------------|----------|---------|----------|------|
| **Age at admission**                                 |          |         |          |      |
| ≤19                                                   | 0.9(2)   | 0.7(2)  | 0.7(4)   | 0.31 |
| 20–29                                                 | 4.7(11)  | 5(15)   | 4.9(26)  |      |
| 30–39                                                 | 12.4(29) | 16.3(49)| 14.6(78) |      |
| 40–49                                                 | 20.5(48) | 15.9(48)| 17.9(96) |      |
| 50–59                                                 | 25.6(60) | 23.6(71)| 24.5(131)|      |
| 60–69                                                 | 22.6(53) | 18.3(55)| 20.2(108)|      |
| 70–79                                                 | 7.3(17)  | 11(33)  | 9.3(50)  |      |
| ≥80                                                   | 6(14)    | 9.3(28)| 7.9(42)  |      |
| **Diabetes**                                          |          |         |          |      |
| Yes                                                   | 35.3(77) | 26.1(74)| 30.1(151)| 0.02 |
| No                                                    | 64.7(141)| 73.9(210)| 69.9(351)|      |
| **Hypertension (HTN)**                               |          |         |          |      |
| Yes                                                   | 42.2(92) | 26.8(76)| 33.5(168)| 0.001|
| No                                                    | 57.8(126)| 73.2(208)| 66.5(334)|      |
| **Asthma or chronic obstructive pulmonary disease (COPD)** |          |         |          |      |
| Yes                                                   | 17.4(38) | 19.4(55)| 18.5(93) | 0.58 |
| No                                                    | 82.6(180)| 80.6(229)| 81.5(409)|      |
| **Malignancy**                                        |          |         |          |      |
| Yes                                                   | 4.6(10)  | 4.6(13) | 4.6(23)  | 0.99 |
| No                                                    | 95.4(208)| 95.4(271)| 95.4(479)|      |
| **Organ transplant**                                  |          |         |          |      |
| Yes                                                   | 0(0)     | 0.4(1)  | 0.4(1)   | 0.37 |
| No                                                    | 100(219) | 99.6(282)| 99.6(501)|      |
| **Other chronic conditions**                          |          |         |          |      |
| Yes                                                   | 74.3(162)| 60.9(173)| 66.7(335)| 0.002|
| No                                                    | 25.7(56) | 39.1(111)| 33.3(167)|      |
| **Smoker**                                            |          |         |          |      |
| Yes                                                   | 0.6(1)   | 4.6(11) | 3(12)    | 0.02 |
| No                                                    | 99.4(163)| 95.4(228)| 97(391)  |      |
| **Addictions**                                        |          |         |          |      |
| Yes                                                   | 2.4(4)   | 4.2(10) | 3.5(14)  | 0.34 |
| No                                                    | 97.6(160)| 95.8(229)| 96.5(389)|      |
| **Initial Lung CT result**                            |          |         |          |      |
| Positive                                              | 6.9(15)  | 6.7(19) | 6.8(34)  | 0.93 |
| Negative                                              | 93.1(203)| 93.3(265)| 93.2(468)|      |
| **CT scan results during discharge**                  |          |         |          |      |
| Positive                                              | 73.9(17)| 89.7(26)| 82.7(43) | 0.13 |
| Negative                                              | 26.1(6) | 10.3(3) | 17.3(9)  |      |
| **Patient admission**                                 |          |         |          |      |
| Inpatient                                             | 95.3(222)| 97.4(296)| 96.5(518)| 0.19 |
| Outpatient                                            | 4.7(11)  | 2.6(8)  | 3.5(19)  |      |
| **ICU admission**                                     |          |         |          |      |
| Yes                                                   | 11.7(26) | 13.2(39)| 12.5(65) | 0.61 |
| No                                                    | 88.3(196)| 86.8(257)| 87.5(453)|      |
| **Outcomes**                                          |          |         |          |      |
| Partial recovery                                      | 3.9(9)   | 7(21)   | 5.7(30)  | 0.08 |
| Recovery                                              | 82(187)  | 76.5(231)| 78.9(418)|      |
| Death                                                 | 7(16)    | 9.3(28) | 8.3(44)  |      |
| Unknown                                               | 7.1(16)  | 7.2(22) | 7.1(38)  |      |
| **Initial symptoms**                                  |          |         |          |      |
| Fever chill                                           |          |         |          |      |
| Yes                                                   | 55.4(128)| 61.5(184)| 58.9(312)| 0.15 |
| No                                                    | 44.6(103)| 38.5(115)| 41.1(218)|      |
| Cough                                                 |          |         |          |      |
| Yes                                                   | 76.2(176)| 72.2(216)| 74.9(392)| 0.3 |
| No                                                    | 23.8(55) | 27.8(83)| 26(138)  |      |
| Cough (sputum)                                        |          |         |          |      |
| Yes                                                   | 17.7(41) | 17.4(52)| 17.5(93) | 0.091|
| No                                                    | 82.3(190)| 82.6(247)| 82.5(437)|      |
| Shortness of breath                                   |          |         |          |      |
| Yes                                                   | 65.8(152)| 67.6(202)| 66.8(354)| 0.67 |
| No                                                    | 34.2(79) | 32.4(97)| 33.2(176)|      |
treatment, univariate logistic regression was used. The results are shown in the Table 3 and Fig. 2. This step of the analysis was performed to identify effective variables that have significant potential for entering multivariate logistic regression. Variables with a significance level of less than 0.3 were selected for the final analysis. According to the Table 3, the

### Table 1 (Continued)

| Characteristics | Female | Male | All | Sig |
|-----------------|--------|------|-----|-----|
| Myalgia         |        |      |     |     |
| Yes             | 8.7(20)| 7(21)| 7.7(41)| 0.48 Chi-Square |
| No              | 91.3(211)| 93(278)| 92.3(489)| |
| Headache        |        |      |     |     |
| Yes             | 14.3(33)| 11(33)| 12.5(66)| 0.26 Chi-Square |
| No              | 85.7(198)| 89(266)| 87.5(464)| |
| Fatigue         |        |      |     |     |
| Yes             | 16.5(38)| 16.1(48)| 16.2(86)| 0.90 Chi-Square |
| No              | 83.5(193)| 83.9(251)| 83.8(444)| |
| Chest pain      |        |      |     |     |
| Yes             | 5.2(12)| 6.4(19)| 5.8(31)| 0.57 Chi-Square |
| No              | 94.8(219)| 93.6(280)| 94.2(499)| |
| Runny nose      |        |      |     |     |
| No              | 100(231)| 100(229)| 100(530)| |
| Sore throat     |        |      |     |     |
| Yes             | 3(7)| 3.7(11)| 3.4(18)| 0.68 Chi-Square |
| No              | 97(224)| 96.3(288)| 96.6(512)| |
| Nausea/vomiting |        |      |     |     |
| Yes             | 13.9(32)| 10.4(31)| 11.9(63)| 0.22 Chi-Square |
| No              | 86.1(199)| 89.6(267)| 88.1(466)| |
| RT-PCR          |        |      |     |     |
| Not taken       | 94.9(224)| 92.5(284)| 93.6(508)| 0.5 Chi-Square |
| Positive        | 3.8(9)| 5.2(16)| 4.6(25)| |
| Negative        | 1.3(3)| 2.3(7)| 1.8(10)| |

Table 2 – Laboratory data of COVID-19 patients with and without oseltamivir medication regimen. Values are expressed as median rank (mean rank).

| Laboratory data          | Medication regimen containing Oseltamivir | Medication regimen without Oseltamivir | All | sig |
|--------------------------|-------------------------------------------|----------------------------------------|-----|-----|
| Leukocyte count (×10^3/μL) | Initial 61.8 (269) | 38.2 (166) | 435 | 0.53 |
|                         | discharge 64.5 (53) | 35.5 (29) | 82  | 0.85 |
| Lymphocyte count (×10^3/μL) | Initial 61.8 (269) | 38.2 (166) | 428 | 0.04 |
|                         | discharge 64.5 (53) | 35.5 (29) | 82  | 0.78 |
| Neutrophil count (×10^3/μL) | Initial 61.4 (263) | 38.6 (165) | 428 | 0.83 |
|                         | discharge 64 (52) | 36 (29) | 81  | 0.98 |
| Platelet count (×10^3/μL)  | Initial 62 (263) | 38 (163) | 426 | 0.11 |
|                         | discharge 64 (52) | 36 (29) | 81  | 0.37 |
| ESR (mm/h)               | Initial 61 (188) | 39 (120) | 308 | 0.55 |
|                         | discharge 56.7 (21) | 43.3 (16) | 37  | 0.74 |
| CRP                      | Initial 63.5 (241) | 36.5 (138) | 379 | 0.03 |
|                         | discharge 71.1 (37) | 28.9 (15) | 52  | 0.59 |
| LDH (U/L)                | Initial 60.7 (193) | 39.3 (125) | 318 | 0.01 |
|                         | discharge 66.7 (20) | 33.3 (10) | 30  | 0.11 |
| Cr                       | Initial 63 (263) | 37 (155) | 418 | 0.74 |
|                         | discharge 55.5 (65) | 44.5 (52) | 117 | 0.05 |
| AST (mg/dL)              | Initial 64.5 (201) | 35.5 (111) | 312 | 0.20 |
|                         | discharge 57.4 (27) | 42.6 (20) | 47  | 0.49 |
| ALT (U/L)                | Initial 64.3 (200) | 35.7 (111) | 311 | 0.26 |
|                         | discharge 57.4 (27) | 42.6 (20) | 47  | 0.48 |
| PTT (Sec)                | Initial 63.3 (50) | 36.7 (29) | 79  | 0.41 |
|                         | discharge 44.1 (15) | 55.9 (19) | 34  | 0.25 |
| PT (Sec)                 | Initial 62.8 (49) | 37.2 (29) | 78  | 0.13 |
|                         | discharge 44.1 (15) | 55.9 (19) | 34  | 0.30 |
| INR                      | Initial 62.5 (47) | 37.5 (28) | 75  | 0.10 |
|                         | discharge 45.1 (14) | 54.9 (17) | 31  | 0.25 |
| BillT (mg/dL)            | Initial 63 (149) | 37 (89) | 238 | 0.16 |
|                         | discharge 72 (16) | 27 (36) | 22  | 0.73 |
The effect of oseltamivir was not significant with respect to the p-value (p = 0.99). Therefore, it did not enter the multivariate model. Smoking, lung disease, malignancy, hypertension, and patient gender were included in the multivariate model and the model was implemented as follows.

According to the variables of Table 4, the patients with lung disease have a 4.48 (1.35, 14.94) higher rate of death than those without the disease (P = 0.014). Moreover, the death rate in patients with malignancy is higher than patients without malignancy (P = 0.027). Patients with cigarette history in the hospital were 23.26 (5.07, 111.11) more likely to die than those without a history of smoking (P < 0.001). Patients with a history of hospitalization for any reason have a 15.38 (5.56, 41.67) higher rate of death than those without a history of hospitalization (P < 0.001). Kaplan-Meyer method was used to compare the duration of treatment in patients receiving oseltamivir versus those who did not receive it, and the mean hospital stay in patients receiving oseltamivir was 5.57 (5.20, 5.94) days. The group that did not receive was 5.55 (5.01, 6.09) days, which was compared using the logrank test and no significant difference was observed (P = 0.654) (Table 5).

Discussion

This study was one of the few retrospective cohort studies that investigated the effect of oseltamivir prescription for patients with COVID-19. To date, a large numbers of antiviral drugs has been tested to find some positive results against COVID-19 infection and also its consequences such as pneumonitis. A computational study suggested that oseltamivir may be useful for fighting against SARS-CoV-2. Furthermore, a case study suggested that oseltamivir may be safe for patients with COVID-19. However, hydroxychloroquine another famous drug during COVID-19 may lead to serious side effects. Experimental and clinical studies are ongoing to determine the possible beneficial effects of various antiviral drugs against COVID-19.

![Survival Functions](image)

**Fig. 2** – Survival rate for patients with COVID-19 following treatment with or without oseltamivir.

### Table 3 – Determining effect of oseltamivir and other factors on the treatment of COVID-19 patients using univariate logistic regression.

| Variable                          | B     | S.E. | Odds Ratio | 95% C.I for Odds Ratio | Sig |
|-----------------------------------|-------|------|------------|------------------------|-----|
| Gender (Male/Female)              | −0.584| 0.539| 0.557      | 0.194 1.603            | 0.278|
| HTN (No/Yes)                      | −0.997| 0.557| 0.369      | 0.124 1.100            | 0.074|
| Asthma and COPD (No/Yes)          | 0.230 | 0.662| 1.259      | 0.344 4.607            | 0.728|
| Lung Disease (No/Yes)             | −1.559| 0.662| 0.210      | 0.057 0.771            | 0.019|
| Malignancy (No/Yes)               | −1.671| 0.718| 0.188      | 0.046 0.768            | 0.020|
| DM (No/Yes)                       | −0.165| 0.562| 0.848      | 0.282 2.552            | 0.769|
| Smoking (No/Yes)                  | −2.826| 0.851| 0.059      | 0.011 0.314            | 0.001|
| Addiction (No/Yes)                | −1.328| 1.067| 0.265      | 0.033 2.146            | 0.213|
| Fever (No/Yes)                    | 0.490 | 0.483| 1.633      | 0.634 4.207            | 0.310|
| Cough (No/Yes)                    | 0.082 | 0.550| 1.086      | 0.370 3.188            | 0.881|
| Oseltamivir (No/Yes)              | −0.008| 0.504| 0.993      | 0.370 2.666            | 0.988|
| Hospitalization history (No/Yes)  | −2.595| 0.542| 0.075      | 0.026 0.216            | <0.001|
| Constant                          | 7.208 | 1.378| 1350.796   |                        |     |
types of drugs such as antiviral, anti-inflammatory and also natural drugs to reduce time of hospitalization, alleviate side effects and improve survival rate.43,44

In the current clinical study, we aimed to evaluate possible positive effects of oseltamivir for COVID-19 patients. Patients with different sex and age included within study. Other possible interventions such as underlying medical conditions, smoking, lung diseases and malignancy considered and some endpoints such as CT scan of lung, blood test, fever and other patient’s conditions were checked. Our investigations showed that patients with malignancy or respiratory diseases have higher risk for death. Furthermore, smoking led to more mortality in COVID-19 patients than those without a history of smoking. A history of hospitalization has also caused a similar result. For evaluating the effect of administration of oseltamivir on survival rate and hospitalization time duration we used Kaplan-Meier analyses test. Results indicated that treatment with oseltamivir can’t reduce the duration time of hospitalization. Furthermore, no increase in survival observed following treatment with oseltamivir. Multivariable logistic regression analyses confirmed that oseltamivir had no improvement in recovery or survival. Multivariable logistic regression analyses also indicated that hospitalization, smoking, malignancy and hypertension are associated with more mortality in patients with COVID-19.

Blood analyses test showed that oseltamivir can’t change most of parameters. However, CRP level reduced at the first stage of oseltamivir administration and lymphocytes count increased. CRP is a critical parameter for infection and inflammatory disorders and it has used as a marker for early detection of infection with SARS-CoV-2. It has reported that the level of CRP has a direct correlation with severity of COVID-19 symptoms.45 CRP level can reflect the severity of pneumonitis in patients with COVID-19.46 Logistic regression analyses showed that treatment with oseltamivir can be effective for patients with lung disease. This result may indicate that oseltamivir may be useful for alleviation of lung pneumonitis. One of the limitations of this study was the non-confirmation of COVID-19 in all patients because at the beginning of the pandemic, molecular testing was not possible for all patients and the diagnosis of COVID-19 in most cases was based on CT scan findings and laboratory data.

To date, some other studies have evaluated the efficiency and the safety of oseltamivir for COVID-19 patients. A study suggested that oseltamivir isn’t suitable for patients with COVID-19. This study compared the structure of proteins in COVID-19 and influenza. Furthermore, they analyzed molecular docking for binding of oseltamivir with key proteins in these viruses. The results suggested that oseltamivir can’t bind to active site of COVID-19. The results also suggested that oseltamivir isn’t effective against COVID-19 and can’t improve the patients’ symptoms.47 Results of this study were agree with our results in the current study. By contrast, another study suggested that oseltamivir can be recommended to improve symptoms and survival rate following infection with COVID-19. This study compared the efficacy of two different regimens including Azithromycin and Hydroxychloroquine or oseltamivir for patients with COVID-19. Results of this study suggested that administration of oseltamivir is more effective for the treatment of COVID-19. Patients that received oseltamivir showed a shorter hospitalization time and faster recovery compared to patients that received Azithromycin and Hydroxychloroquine. Furthermore, patients that received oseltamivir showed a lower mortality.48

Table 4 – Determining effect of different factors on the treatment of COVID-19 patients using multivariate logistic regression.

| Variable                | B     | S.E.  | Odds Ratio | 95% C.I for Odds Ratio | P-value |
|-------------------------|-------|-------|------------|------------------------|---------|
| HTN(No/Yes)             | −0.882| 0.479 | 0.414      | 0.162–1.058             | 0.065   |
| Lung Disease(No/Yes)    | −1.500| 0.612 | 0.223      | 0.067–0.741             | 0.014   |
| Malignancy(No/Yes)      | −1.509| 0.681 | 0.221      | 0.058–0.840             | 0.027   |
| Smoking(No/Yes)         | −3.156| 0.781 | 0.043      | 0.009–0.197             | <0.001  |
| Hospitalization history (No/Yes) | −2.729| 0.518 | 0.065      | 0.024–0.180             | <0.001  |
| Constant                | 6.625 | 0.804 | 753.351    | 0.654                   |         |

Table 5 – Comparison of hospitalization time in the COVID-19 patients with and without oseltamivir medication regimen using logrank test.

| Oseltamivir | Mean Estimate | Std. Error | 95% Confidence Interval | Median Estimate | Std. Error | 95% Confidence Interval | Sig |
|-------------|---------------|------------|-------------------------|----------------|------------|-------------------------|-----|
|             | Hospitalization Time |          | Lower Bound | Upper Bound |           | Lower Bound | Upper Bound |     |
| No          | 5.546          | 0.275      | 5.006       | 6.086       | 5.000      | 0.191       | 4.625       | 5.375 | 0.654 |
| Yes         | 5.568          | 0.251      | 5.075       | 6.060       | 5.000      | 0.205       | 4.599       | 5.401 |
| Overall     | 5.567          | 0.189      | 5.196       | 5.937       | 5.000      | 0.142       | 4.721       | 5.279 |

Conclusion

Oseltamivir administration for COVID-19 patients didn’t cause any increase in survival rate during 1 month following starting treatment. Furthermore, no improvement in
treatment duration and hospitalization time observed following treatment with oseltamivir. However, oseltamivir may be useful for reduction of pneumonitis via reduction of CRP, and it may boost immune system via an increase in lymphocytes count.

**Conflict of interest**

The authors declared no potential conflicts of interest with respect to the research, authorship, and publication of this article.

**Acknowledgments**

This study was supported by a grant from Mazandaran University of Medical Sciences, Sari, Iran.

**REFERENCES**

1. Kaffashian MR, Shirani M, Koupaei M, Sadeghifard N, Ahmadi I, Mezafari A, et al. Clinical Manifestations, imaging procedures and laboratory parameters among hospitalized patients with COVID-19 in Isfahan Province, Western Iran. Ethiop J Health Sci. 2022;32(3).
2. Liu W, Zhang Q, Chen J, Xiang R, Song H, Shu S, et al. Detection of Covid-19 in children in early January 2020 in Wuhan. China New England J Med. 2020;382(14):1370–1.
3. Koupaei M, Shadab Mehr N, Mohammad MH, Asadi A, Abbassimoghaddam S, Shekhtarkar A, et al. Clinical symptoms, diagnosis, treatment, and outcome of COVID-19-associated encephalitis: A systematic review of case reports and case series. J Clin Lab Anal. 2022;36(5), e24426.
4. Ji Y, Ma Z, Peppelenbosch MP, Pan Q. Potential association between COVID-19 mortality and health-care resource availability. Lancet Glob Health. 2020;8(4), e480.
5. Covid C, Team R, COVID C, Team R, Bialek S, Boundy E, et al. Severe outcomes among patients with coronavirus disease 2019 (COVID-19)—United States, February 12–March 16, 2020. Morb Mortal Weekly Rep. 2020;69(12):343.
6. Mousavi SF, Ebrahimi M, Moghaddam SAA, Moafi N, Jafari M, Tavakolian A, et al. Evaluating the characteristics of patients with SARS-CoV-2 infection admitted during COVID-19 peaks: A single-center study. Vacunas. 2022.
7. Driggin E, Madhavan MV, Bikdeli B, Chuich T, Laracy J, Biondi-Zoccai G, et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am Coll Cardiol. 2020;75(18):2352–71.
8. Muniyappa R, Gubbi S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. Am J Physiol Endocrinol Metabol. 2020;318(5):E736–E41.
9. Pan F, Ye T, Sun P, Gui S, Liang B, Li L, et al. Time course of lung changes on chest CT during recovery from 2019 novel coronavirus (COVID-19) pneumonia. Radiology. 2020;200370.
10. Fang L, Karakulakos G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(6), e21.
11. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020;97(5):829–38.
12. Choi WY. Mortality rate of patients with COVID-19 based on underlying health conditions. Disaster Med Public Health Prep. 2021;1-6.
13. Koupaei M, Mohamadi MH, Yashmi I, Shahabi AH, Shabani AH, Heidary M, et al. Clinical manifestations, treatment options, and comorbidities in COVID-19 relapse patients: A systematic review. J Clin Lab Anal. 2022;36(5), e24402.
14. Naimi A, Yashmi I, Jebeli R, Imani Mofrad M, Azimian Abhar S, Jannessar Y, et al. Comorbidities and mortality rate in COVID-19 patients with hematological malignancies: A systematic review and meta-analysis. J Clin Lab Anal. 2022;36(5), e24387.
15. Raoofi A, Takian A, Sari AA, Olyaeeanamesh A, Haghhighi H, Aarabi M. COVID-19 pandemic and comparative health policy learning in Iran. Arch Iran Med. 2020;23(4):220–34.
16. Heidary M, Kaviar VH, Shirani M, Ghanavati R, Motahar M, Sholeh M, et al. A comprehensive review of the protein subunit vaccines against COVID-19. Front Microbiol. 2022;13, 927306.
17. Khoshnood S, Arshadi M, Akrami S, Koupaei M, Ghahramanpour H, Shariati A, et al. An overview on inactivated and live-attenuated SARS-CoV-2 vaccines. J Clin Lab Anal. 2022;36(5), e24418.
18. Khoshnood S, Ghanavati R, Shirani M, Ghahramanpour H, Sholeh M, Shariati A, et al. Viral vector and nucleic acid vaccines against COVID-19: a narrative Review. Front Microbiol. 2022:3379.
19. Le L, Lee E, Truong T, Schulten K. Molecular modeling of swine influenza A/H1N1, Spanish H1N1, and avian H5N1 flu N1 neuraminidases bound to Tamiflu and Relenza. PLoS Curr. 2009:1.
20. Ward P, Small I, Smith J, Suter P, Dutkowski R. Oseltamivir (Tamiflu®) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother. 2005;55 (suppl. 1):i5–21.
21. Collins FJ, Haire LF, Lin YP, Liu J, Russell RJ, Walker PA, et al. Crystal structures of oseltamivir-resistant influenza virus neuraminidase mutants. Nature. 2008;453(7199):1258–61.
22. Mohan S, McAtamney S, Haselhorst T, von Itzstein M, Pinto BM. Carbocycles related to oseltamivir as influenza virus group-1-specific neuraminidase inhibitors. Binding to N1 enzymes in the context of virus-like particles. J Med Chem. 2010;53(20):7377–91.
23. Kmietowicz Z. Tamiflu reduces complications of flu, new review finds. BMJ. 2015;350, h537.
24. Fang Y, Zhang H, Xie J, Lin M, Ying L, Pang P, et al. Sensitivity of chest CT for COVID-19: comparison to RT-PCR. Radiology. 2020;296(2) E115-E7.
25. Azadbakht J, Khoramian D, Lajevardi ZS, Elikaii F, Aflatoonian AH, Farhood B, et al. A review on chest CT scanning parameters implemented in COVID-19 patients: bringing low-dose CT protocols into play. Egypt J Radiol Nucl Med. 2021;52(1):1–10.
26. Mair MD, Hussain M, Siddiqui S, Das S, Baker A, Conboy P, et al. A systematic review and meta-analysis comparing the diagnostic accuracy of initial RT-PCR and CT scan in suspected COVID-19 patients. Br J Radiol. 2021;94 (1119):20201039.
27. Khan MA, Hussain N, Majid A, Alhaisoni M, Bukhari SAC, Kadry S, et al. Classification of positive COVID-19 CT scans using deep learning.; 2021.
28. Mukherjee H, Ghosh S, Dhar A, Obaidullah SM, Santosh K, Roy K. Deep neural network to detect COVID-19: one architecture — United States, February 12–March 16, 2020. Morb Mortal Weekly Rep. 2020;69(12):343.
29. Alshazly H, Linse C, Barth E, Martinetz T. Explainable COVID-19 detection using chest CT scans and deep learning. Sensors. 2021;21(2):455.
30. Oulefki A, Agaian S, Trongtirakul T, Laouar AK. Automatic COVID-19 lung infected region segmentation and measurement using CT-scans images. Pattern Recogn. 2021;114, 107747.

31. Baratella E, Roman-Pognuz E, Zerbato V, Minelli P, Cavallaro MFM, Cova MA, et al. Potential links between COVID-19-associated pulmonary aspergillosis and bronchiectasis as detected by high resolution computed tomography. Front Biosci Landmark. 2021;26(12):1607–12.

32. Benmalek E, Elhamdi M, Jilbab A. Comparing CT scan and chest X-ray imaging for COVID-19 diagnosis. Biomed Eng Adv. 2021;1, 100003.

33. Carvalho ED, Silva RR, Araújo FH, de Al Rabelo R, de Carvalho Filho AO. An approach to the classification of COVID-19 based on CT scans using convolutional features and genetic algorithms. Comput Biol Med. 2021;136:104744.

34. Kalil AC. Treating COVID-19—off-label drug use, compassionate use, and randomized clinical trials during pandemics. JAMA. 2020;323(19):1897–8.

35. Lythgoe MP, Middleton P. Ongoing clinical trials for the management of COVID-19 pandemic. Trends Pharmacol Sci. 2020;41(6):363–82.

36. Gavriatopoulou M, Ntanasis-Stathopoulos I, Korompoki E, Fotiou D, Migkou M, Tranninis I-C, et al. Emerging treatment strategies for COVID-19 infection. Clin Exp Med. 2021;21(2):167–79.

37. Vitiello A, Ferrara F, Porta RL. Remdesivir and COVID-19 infection, therapeutic benefits or unnecessary risks? Ir J Med Sci. 2021;190(4):1637–8.

38. Pourkarim F, Pourtaghi-Anvarian S, Rezaee H. Molnupiravir: A new candidate for COVID-19 treatment. Pharmacol Res Perspect. 2022;10(1), e00909.

39. Muralidharan N, Sakhthivel R, Velmurugan D, Gromiha MM. Computational studies of drug repurposing and synergism of lopinavir, oseltamivir and ritonavir binding with SARS-CoV-2 Protease against COVID-19. J Biomol Struct Dyn. 2020;1-6.

40. Kutlu Ö, Metin A. A case of exacerbation of psoriasis after oseltamivir and hydroxychloroquine and bronchiectasis as detected by high resolution computed tomography. Front Biosci Landmark. 2021;26(12):1607–12.

41. Sogut O, Can MM, Guven R, Kaplan O, Ergenc H, Umit TB, et al. Safety and efficacy of hydroxychloroquine in 152 outpatients with confirmed COVID-19: a pilot observational study. Am J Emerg Med. 2021;40:41–6.

42. Izovich C, Siemieniuk RA, Bartoszko JJ, Ge L, Zeraatkar D, Kum E, et al. Adverse effects of remdesivir, hydroxychloroquine and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomised trials. BMJ Open. 2022;12(3), e048502.

43. Stebbing J, Phelan A, Griffin I, Tucker C, Oechsle O, Smith D, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020;20(4):400–2.

44. Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Therapeut. 2020;14(1):58–60.

45. Liu F, Li L, Xu M, Wu J, Luo D, Zhu Y, et al. Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19. J Clin Virol. 2020;127, 104370.

46. Wang L. C-reactive protein levels in the early stage of COVID-19. Med Mal Infect. 2020;50(4):332–4.

47. Tan Q, Duan L, Ma Y, Wu F, Huang Q, Mao K, et al. Is oseltamivir suitable for fighting against COVID-19: In silico assessment, in vitro and retrospective study. Bioorg Chem. 2020;104, 104257.

48. Zendehdel A, Bidkhori M, Ansari M, Jamalimoghaddosstakhkali S, Asoodeh A. Efficacy of oseltamivir in the treatment of patients infected with Covid-19. Ann Med Surg (Lond). 2022;77, 103679.